Gordon Guo MD

Board Certified Radiation Oncologist and Assistant Professor
University Hospitals/Case Western Reserve University
Seidman Cancer Center, Cleveland, OH
Professional Email : gordon.guo@uhhospitals.org
Personal Email : gordonz_guo@hotmail.com
Cell 646-915-5886

Clinical expertise

- Brachytherapy (prostate HDR/LDR, GYN HDR)
- LINAC-based SRS (CNS, spine), SBRT (lung, liver, prostate), IMRT
- Proton therapy

Professional Memberships & committees

National

American Society of Radiation Oncology (ASTRO)	Member
American Brachytherapy Society (ABS)	Member
NRG GU committee	Committee Member
NRG Cervix cancer committee	Committee Member
ABR Online Longitudinal Assessment (OLA) For Radiation oncology Question Writing Committee	Committee Member

Hospital

CWRU Radiation Research Safety Committee (RRSC)	Committee Member
Faculty Recruitment Committee	Committee Member
Medical Residency Interview Committee	Committee Member

Faculty

Current position
Assistant Professor, June 2020 – present
GU service Director, Brachytherapy Service Chief

- SBRT (Lung, liver, spine), LDR brachytherapy, complex GYN HDR brachytherapy
- Site PI of GU and GYN clinical trials

Department of Radiation Oncology, University Hospitals Seidman Cancer Center
Cleveland OH

Assistant Professor – Indiana University Simon Cancer Center Aug 2016 – May 2020
GU/GYN service chief
Brachytherapy service Chief

- re-built a high-volume GU service and prostate brachytherapy program
- Treated large number of H&N, thoracic and CNS patients

Indianapolis, IN

Residency & Fellowship

Brachytherapy Fellowship, Mount Sinai Beth Israel — Jul. 2015 – June 2016
New York, NY, USA

Radiation Oncology Residency, University of Manitoba — Jul. 2010 – Jun. 2015
Winnipeg, Manitoba, Canada

Resident elective, MD Anderson Cancer Center — Oct. 2013– Dec. 2013
Houston, TX, USA

Education

Doctor of Medicine, University of Toronto — Sept. 2003 – Apr. 2007
Toronto, Ontario, Canada

Bachelor of science (biochemistry), University of Waterloo — Sept. 1999 – Apr. 2003
Waterloo, Ontario, Canada

Academic Profile

Clinical Trials (as Institution PI)

GU005 Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk Prostate cancer

PARTIQoL : Prostate Advanced Radiation Technologies Investigating Quality of Life; A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for low or Intermediate Risk prostate Cancer

RTOG 3506 STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA recurrences with Aggressive Disease Features

COMPPARE : A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

Venezia-CIP-001 / EBV 1819 Multi-Center Prospective Observational Clinical Follow-up Study Advanced Gynecological Applicator –Venezia Configuration

HCRN GU16-243: Phase I trial of Durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non-muscle invasive bladder cancer patients

Investigator Initiated Trials (as PI)

Phase II study of Metastasis-Directed SBRT with Adjuvant Immunotherapy for Oliometastatic Castrate-Resistant Prostate Cancer

Phase II study of SBRT with Neoadjuvant Immunotherapy for Unresectable Renal Cell Carcinoma and Assay of Propensity For Inmmune Modulation

Conference presentations

McClelland S 3rd, Le Y, Ng SK, **Guo** GZ: *Can HDR Brachytherapy Achieve superior Proximal Seminal Vesicle Coverage to LDR brachytherapy? A DOsimetric Comparison of two Brachytherapy Boost Modalities*. Abstract 20000697, Radiological Society of North America, 106th Annual Meeting, 2020.

Yi Le, Zheng Gu, Matthew Napiwocki, Gordon Watson, **Gordon Guo** *A plan quality assurance (QA) method for HDR breast brachytherapy with multi-lumen balloon applicator and HDR interstitial prostate brachytherapy* American Brachytherapy Society Meeting, Miami, FL, 2019

Hinton J, Schilder J, **Guo, G.** *High-dose-rate Brachytherapy following concurrent chemoradiotherapy for locally advanced cervical cancer: Early outcomes after adoption of MRI-Guided 3-D volumetric planning* American Brachytherapy Society Annual Meeting, San Francisco, CA. 2018

Gordon Guo, Lawrence Tena, Tracy Ng. *High-dose-rate Brachytherapy boost in addition to IMRT for nasopharyngeal carcinoma* ASTRO Annual Scientific Meeting, Boston, MA. 2016

Gordon Guo, Pascal Lambert, Naseer Ahmed, Garry Schroeder, Derek Fewer, Shaun Loewen. *Aggressive local therapy may improve survival in NSCLC patients with limited brain metastases* ASTRO Annual Scientific Meeting, San Francisco, CA. 2014

Gordon Guo, Candace Myers, Keith Sutherland, Pascal Lambert, Jim Butler, Harvey Quon. *Prospective swallowing outcomes after IMRT for oropharyngeal cancer: dosimetric correlations in a population-based cohort.* ASTRO Annual Scientific Meeting, International Journal of Radiation Oncology * Biology * Physics Vol. 84, Issue 3, Supplement, Page S480. Boston, MA. 2012

Goldstein, J., **Guo, G**., Li,C., S.E. Quaggin. *A simple and reproducible genetic model to study glomerulosclerosis in the mouse*. American Society of Nephrology 39th Annual Renal Week Meeting. San Diego, CA. 2006

Cui, S., Li, J., **Guo, G**., S.E. Quaggin. *Innocent bystander theory for progression to glomerulosclerosis in a transgenic mouse model*, American Society of Nephrology, St. Louis, MO. 2004

Gordon Guo, Debra J. Morrison, Jonathan D. Licht and Susan E. Quaggin. *The Wilms Tumor Suppressor Gene binds to a podocyte-specific enhancer from the Human Nephrin* Gene. Annual Conference of American Society of nephrology, San Diego, CA. 2003

Gordon Guo, Chenglin Li, Vera Eremina, and Susan E. Quaggin. *Podocytopenia leads to glomerulosclerosis in transgenic mice*. Annual Conference of American Society of nephrology, San Diego, CA. 2003

Book

Tirkes, Temel (Ed.) Prostate MRI Essentials – A Practical Guide for Radiologists
Hardcover ISBN 978-3-030-45934-5 eBook ISBN 978-3-030-45935-2
Springer International Publishing 2020
Chapter 11: Prostate MRI from Radiation Oncology Perspective

Publications in peer-reviewed journals

Gordon Guo, Zainab Almomen, Brady Cripe, Drew Hedges, William Rios Izquierdo The Planned vs Actual Dosimetric Effect of Bladder Filling on Patients receiving salvage pelvic radiotherapy after prostatectomy Accepted for publication. Radiation Therapist 2021

Gordon Guo, Keith Sutherland, Candace Myers Pascal Lambert, Harvey Quon. Prospective swallowing outcomes after IMRT for oropharyngeal cancer: dosimetric correlations in a population-based cohort. *Oral Ocology*. 2016 Oct; 61:135-41

Henan Zhao, Xiaotang Yu, Yanfang Ding, Jinyao Zhao, Guang Wang, Xian Wu, Jiyong Jiang, Chun Peng, **Gordon Zhuo Guo**, Shiying Cui. MiR-770
5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2
Oncotarget. 2016 Aug 16; 7(33): 53254–53268

Zhao H, Liu S, Wang G, Wu X, Ding Y, **Guo G**, Jiang J, Cui S Expression of mir-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. *Oncology reports* 2015;33:591-598.

Zhang X, **Guo G**, Wang G, et al. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of mir-510 in ovarian carcinoma. *Molecular medicine reports* 2015;12:8021-8031.

Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, Jia T, Han D, **Guo G,** Wang B, Jiang J, Cui S. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biology 2013;34:3501-3508.

Zhao JY, Liu CQ, Zhao HN, Ding YF, Bi T, Wang B, Lin XC, **Guo G**, Cui SY.

Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: Applications in clinical and basic research. Methods. 2012;58:156-163.

Guo G, Morrison DJ, Licht JD and Quaggin SE. WT1 activates a glomerular-specific enhancer identified from the Human Nephrin Gene Journal of American Society of Nephrology: JASN 2004;15:2851-2856.